EyeBio Announces Positive Visual, Anatomic and Safety Data from First-in-Human Ph1b/2a AMARONE Trial of Restoret at Macula Society Annual Meeting

NEW YORK & LONDON--(BUSINESS WIRE)--EyeBio announced the presentation of Week 12 data from its first-in-human Phase 1b/2a AMARONE trial of Restoret in individuals with DME and NVAMD.